Mesh.i
Exploration
Accueil
Racine
Exploration
Accueil

Serveur d'exploration COVID et hydrochloroquine - Exploration (Accueil)

Index « Mesh.i » - entrée « Drug Approval »
Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.
Drug Administration Schedule < Drug Approval < Drug Combinations  Facettes :

List of bibliographic references indexed by Drug Approval

Number of relevant bibliographic references: 12.
Ident.Authors (with country if any)Title
000495 (2021) John G. Rizk [États-Unis] ; Donald N. Forthal [États-Unis] ; Kamyar Kalantar-Zadeh [États-Unis] ; Mandeep R. Mehra [États-Unis] ; Carl J. Lavie [États-Unis] ; Youssef Rizk [Liban] ; Joann P. Pfeiffer [États-Unis] ; John C. Lewin [États-Unis]Expanded Access Programs, compassionate drug use, and Emergency Use Authorizations during the COVID-19 pandemic.
000A87 (2020) Iain Simpson [Royaume-Uni]Therapeutic delivery: industry update covering June 2020.
000C29 (2020) Gayathri VaidyanathanScientists criticize use of unproven COVID drugs in India.
000D39 (2020) Santosh Kumar [États-Unis] ; Kaining Zhi [États-Unis] ; Ahona Mukherji [États-Unis] ; Kelli Gerth [États-Unis]Repurposing Antiviral Protease Inhibitors Using Extracellular Vesicles for Potential Therapy of COVID-19.
000D50 (2020) Susan JaffeRegulators split on antimalarials for COVID-19.
000F37 (2020) Mike Z. Zhai [États-Unis] ; Carolyn T. Lye [États-Unis] ; Aaron S. Kesselheim [États-Unis]Need for Transparency and Reliable Evidence in Emergency Use Authorizations for Coronavirus Disease 2019 (COVID-19) Therapies.
001306 (2020) Sylwester Dro D Al [Pologne] ; Jakub Rosik [Pologne] ; Kacper Lechowicz [Pologne] ; Filip Machaj [Pologne] ; Katarzyna Kotfis [Pologne] ; Saeid Ghavami [Canada] ; Marek J. Łos [Pologne]FDA approved drugs with pharmacotherapeutic potential for SARS-CoV-2 (COVID-19) therapy.
001339 (2020) Kyle Thomson [États-Unis] ; Herschel Nachlis [États-Unis]Emergency Use Authorizations During the COVID-19 Pandemic: Lessons From Hydroxychloroquine for Vaccine Authorization and Approval.
001401 (2020) Benjamin N. Rome [États-Unis] ; Jerry Avorn [États-Unis]Drug Evaluation during the Covid-19 Pandemic.
001412 (2020) Erisa Alia [États-Unis] ; Jane M. Grant-Kels [États-Unis]Does hydroxychloroquine combat COVID-19? A timeline of evidence.
001420 (2020) Shuofeng Yuan ; Jasper F W. Chan [Hong Kong] ; Kenn K H. Chik ; Chris C Y. Chan ; Jessica O L. Tsang ; Ronghui Liang ; Jianli Cao ; Kaiming Tang ; Lin-Lei Chen ; Kun Wen [République populaire de Chine] ; Jian-Piao Cai ; Zi-Wei Ye ; Gang Lu [République populaire de Chine] ; Hin Chu ; Dong-Yan Jin ; Kwok-Yung Yuen [Hong Kong]Discovery of the FDA-approved drugs bexarotene, cetilistat, diiodohydroxyquinoline, and abiraterone as potential COVID-19 treatments with a robust two-tier screening system.
001665 (2020) Tianxiao Liu [États-Unis] ; Songyuan Luo [États-Unis] ; Peter Libby [États-Unis] ; Guo-Ping Shi [États-Unis]Cathepsin L-selective inhibitors: A potentially promising treatment for COVID-19 patients.

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CovidChloroV1/Data/Main/Exploration

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/Mesh.i -k "Drug Approval" 

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/Mesh.i  \
                -Sk "Drug Approval" \
         | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    CovidChloroV1
   |flux=    Main
   |étape=   Exploration
   |type=    indexItem
   |index=    Mesh.i
   |clé=    Drug Approval
}}
Wicri

This area was generated with Dilib version V0.6.38.
Data generation: Sat May 22 17:02:32 2021. Site generation: Sat May 22 17:06:52 2021